Trials / Conditions / Unresectable Breast Cancer
Unresectable Breast Cancer
6 registered clinical trials studyying Unresectable Breast Cancer — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer NCT07193394 | Institut Curie | Phase 2 |
| Recruiting | BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Bre NCT05977036 | Washington University School of Medicine | N/A |
| Completed | HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada NCT06386263 | AstraZeneca | — |
| Recruiting | DESTINY Breast Respond HER2-low Europe NCT05945732 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Withdrawn | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer NCT04872608 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive B NCT04042051 | Cancer Trials Ireland | Phase 1 |